Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans-Reference-Cited by-同舟云学术

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans

Published:2023-03-22 Issue:1 Volume:26 Page:422-429
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Joshi Kruti¹,Pilon Dominic²^ORCID,Shah Aditi²,Holiday Christopher²,Karkare Swapna¹,Zhdanava Maryia²^ORCID

Affiliation:

1. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

2. Analysis Group, Inc., Montréal, QC, Canada

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2188845

Reference18 articles.

1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021.

2. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

3. Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the Medicare population. Rockville (MD): Agency for Healthcare Research and Quality; 2018.

4. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

5. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray;Current Medical Research and Opinion;2024-07-24

2. Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States;Drugs - Real World Outcomes;2024-05-10

3. Psychopharmacological treatment of depression and anxiety and their different drug delivery targets;Current Psychiatry Research and Reviews;2023-08-22

4. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States;Journal of Medical Economics;2023-05-15